Wednesday, July 16, 2025 - British tennis star, Tara Moore has been hit with a four-year doping ban, despite the British tennis player being cleared of wrongdoing just 18 months ago.
The Court of Arbitration for Sport (CAS) has ruled Moore
failed to provide enough evidence to prove her failed drug test from 2022 was
accidental.
Moore, a former British No.1 in doubles, tested positive for
nandrolone and boldenone in May 2022 while competing at a tournament in
Colombia.
Nandrolone and boldenone are anabolic steroids, synthetic
versions of testosterone. The former has been coined ‘the sportsman’s favourite
performance drug’ by The Guardian.
Moore, who has always denied any wrongdoing, was originally
hit with a provisional suspension for over a year before an independent
hearing.
An independent tribunal then ruled that contaminated meat
was the source of her positive drugs test – and that Moore ‘bore no fault or
negligence’.
After the ruling, Moore said she’d been through ’19 months
of lost time and emotional distress’ and argued her reputation had been wrongly
tarnished.
The Briton made her return to the ITF World Tour last year
and was in the draw for Wimbledon, the US Open, and featured at the Australian
Open.
But the International Tennis Integrity Agency (ITIA) issued
an appeal against the decision that she was not responsible for the positive
test.
Following a new CAS hearing, a majority ruling has now sided
with the ITIA, and the 32-year-old’s four-year ban has been subsequently
reimposed.
She will not be allowed to play again until 2028 – although
19 months of her suspension has been deducted – because it’s already been
served.
A statement from CAS read: ‘After reviewing the scientific
and legal evidence, the majority of the CAS Panel considered that the player
did not succeed in proving that the concentration of nandrolone in her sample
was consistent with the ingestion of contaminated meat.
‘The panel concluded that Ms Moore failed to establish that
the ADRV (Anti-Doping Rule Violation) was not intentional.
‘The appeal by the ITIA is therefore upheld and the decision rendered by the Independent Tribunal is set aside.’
Karen Moorehouse, the ITIA’s chief executive, said that Moore failed to sufficiently explain the level of nandrolone in her system at the time.
‘For the ITIA, every case is considered according to the
individual facts and circumstances,’ Moorehouse said.
‘Our bar for appealing a first instance decision is high,
and the decision is not taken lightly.
‘In this case, our independent scientific advice was that
the player did not adequately explain the high level of nandrolone present in
their sample. Today’s ruling is consistent with this position.
‘We understand that players and their support teams may have
questions about this decision, and we will answer these fully once we have
reviewed the details of the ruling.’
0 Comments